WEKO3
アイテム
{"_buckets": {"deposit": "1325ce93-4735-4d8e-adad-72494b2b573d"}, "_deposit": {"id": "3826", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "3826"}, "status": "published"}, "_oai": {"id": "oai:soar-ir.repo.nii.ac.jp:00003826", "sets": ["462"]}, "author_link": ["7311", "7312", "7313", "7314", "7315", "7316", "7317", "7318", "7319"], "item_1628147817048": {"attribute_name": "出版タイプ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_6_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2011-06", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "6", "bibliographicPageEnd": "593", "bibliographicPageStart": "587", "bibliographicVolumeNumber": "41", "bibliographic_titles": [{"bibliographic_title": "HEPATOLOGY RESEARCH"}]}]}, "item_6_description_20": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Aim: Serum chemokine levels and amino acid substitutions in the interferon-sensitivity determining region (ISDR) and core region have been associated with treatment outcome of pegylated interferon and ribavirin therapy in genotype 1 hepatitis C virus (HCV)-infected patients. The present study was conducted to clarify the association between serum chemokines and treatment outcome in patients with chronic HCV-1 infection in a Japanese cohort. Methods: A total of six serum chemokines were quantified before, during and after pegylated interferon and ribavirin treatment in 79 genotype 1 chronic HCV patients using a multiple bead array system. Viral ISDR and core region variants were determined by direct sequencing. Results: The baseline serum levels of eotaxin, IP-10 and RANTES were significantly higher in chronic HCV patients than in controls. High levels of eotaxin and macrophage inflammatory protein (MIP)-1 beta before therapy and more than two mutations in the ISDR were associated with a sustained virological response, and patients with more than two mutations in the ISDR also had significantly higher MIP-1 beta levels. Receiver-operator curve analysis showed a 77% sensitivity and 73% specificity for predicting an SVR using MIP-1 beta values. Conclusion: Serum MIP-1 beta levels may predict the response to HCV treatment with pegylated interferon and ribavirin and are associated with amino acid substitutions in the ISDR.", "subitem_description_type": "Abstract"}]}, "item_6_description_30": {"attribute_name": "資源タイプ(コンテンツの種類)", "attribute_value_mlt": [{"subitem_description": "Article", "subitem_description_type": "Other"}]}, "item_6_description_5": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "HEPATOLOGY RESEARCH. 41(6):587-593 (2011)", "subitem_description_type": "Other"}]}, "item_6_link_3": {"attribute_name": "信州大学研究者総覧へのリンク", "attribute_value_mlt": [{"subitem_link_text": "Umemura, Takeji", "subitem_link_url": "http://soar-rd.shinshu-u.ac.jp/profile/ja.ymSpgpkh.html"}, {"subitem_link_text": "Joshita, Satoru", "subitem_link_url": "http://soar-rd.shinshu-u.ac.jp/profile/ja.PeLNbVym.html"}, {"subitem_link_text": "Ota, Masao", "subitem_link_url": "http://soar-rd.shinshu-u.ac.jp/profile/ja.ZefVOFkh.html"}, {"subitem_link_text": "Tanaka, Eiji", "subitem_link_url": "http://soar-rd.shinshu-u.ac.jp/profile/ja.HFDCHekh.html"}]}, "item_6_link_67": {"attribute_name": "WoS", "attribute_value_mlt": [{"subitem_link_text": "Web of Science", "subitem_link_url": "http://gateway.isiknowledge.com/gateway/Gateway.cgi?\u0026GWVersion=2\u0026SrcAuth=ShinshuUniv\u0026SrcApp=ShinshuUniv\u0026DestLinkType=FullRecord\u0026DestApp=WOS\u0026KeyUT=000290963400012"}]}, "item_6_publisher_4": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "WILEY-BLACKWELL"}]}, "item_6_relation_47": {"attribute_name": "PubMed", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "21504519"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://pubmed.ncbi.nlm.nih.gov/21504519", "subitem_relation_type_select": "PMID"}}]}, "item_6_relation_48": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "10.1111/j.1872-034X.2011.00802.x"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://doi.org/10.1111/j.1872-034X.2011.00802.x", "subitem_relation_type_select": "DOI"}}]}, "item_6_rights_62": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "The definitive version is available at www.blackwell-synergy.com"}]}, "item_6_select_64": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "author"}]}, "item_6_source_id_35": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1386-6346", "subitem_source_identifier_type": "PISSN"}]}, "item_6_source_id_39": {"attribute_name": "NII ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1386-6346", "subitem_source_identifier_type": "PISSN"}]}, "item_6_source_id_40": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_source_identifier": "AA11140867", "subitem_source_identifier_type": "NCID"}]}, "item_6_text_69": {"attribute_name": "wosonly authkey", "attribute_value_mlt": [{"subitem_text_value": "chemokines; core; interferon sensitivity determining region; MIP-1 beta; pegylated interferon; ribavirin"}]}, "item_6_text_70": {"attribute_name": "wosonly keywords", "attribute_value_mlt": [{"subitem_text_value": "NON-B-HEPATITIS; VIRUS-INFECTION; PLUS RIBAVIRIN; HEPATOCELLULAR-CARCINOMA; VIROLOGICAL RESPONSE; VIRAL RESPONSE; LIVER-DISEASE; PLASMA-LEVELS; NON-A; INFLAMMATION"}]}, "item_6_textarea_68": {"attribute_name": "wosonly abstract", "attribute_value_mlt": [{"subitem_textarea_value": "Aim: Serum chemokine levels and amino acid substitutions in the interferon-sensitivity determining region (ISDR) and core region have been associated with treatment outcome of pegylated interferon and ribavirin therapy in genotype 1 hepatitis C virus (HCV)-infected patients. The present study was conducted to clarify the association between serum chemokines and treatment outcome in patients with chronic HCV-1 infection in a Japanese cohort. Methods: A total of six serum chemokines were quantified before, during and after pegylated interferon and ribavirin treatment in 79 genotype 1 chronic HCV patients using a multiple bead array system. Viral ISDR and core region variants were determined by direct sequencing. Results: The baseline serum levels of eotaxin, IP-10 and RANTES were significantly higher in chronic HCV patients than in controls. High levels of eotaxin and macrophage inflammatory protein (MIP)-1 beta before therapy and more than two mutations in the ISDR were associated with a sustained virological response, and patients with more than two mutations in the ISDR also had significantly higher MIP-1 beta levels. Receiver-operator curve analysis showed a 77% sensitivity and 73% specificity for predicting an SVR using MIP-1 beta values. Conclusion: Serum MIP-1 beta levels may predict the response to HCV treatment with pegylated interferon and ribavirin and are associated with amino acid substitutions in the ISDR."}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Yoneda, Suguru", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "7311", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Umemura, Takeji", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "7312", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Joshita, Satoru", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "7313", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ichijo, Tetsuya", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "7314", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Matsumoto, Akihiro", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "7315", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yoshizawa, Kaname", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "7316", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Katsuyama, Yoshihiko", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "7317", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ota, Masao", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "7318", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tanaka, Eiji", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "7319", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2015-09-24"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "Serum_Chemokine_Levels_Are_Associated_Outcome_ Pegylated_Interferon.pdf", "filesize": [{"value": "210.2 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_note", "mimetype": "application/pdf", "size": 210200.0, "url": {"label": "Serum_Chemokine_Levels_Are_Associated_Outcome_ Pegylated_Interferon.pdf", "url": "https://soar-ir.repo.nii.ac.jp/record/3826/files/Serum_Chemokine_Levels_Are_Associated_Outcome_ Pegylated_Interferon.pdf"}, "version_id": "885e681e-835d-46de-8514-d2caef6f6514"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "chemokines", "subitem_subject_scheme": "Other"}, {"subitem_subject": "core", "subitem_subject_scheme": "Other"}, {"subitem_subject": "interferon sensitivity determining region", "subitem_subject_scheme": "Other"}, {"subitem_subject": "MIP-1 beta", "subitem_subject_scheme": "Other"}, {"subitem_subject": "pegylated interferon", "subitem_subject_scheme": "Other"}, {"subitem_subject": "ribavirin", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Serum chemokine levels are associated with the outcome of pegylated interferon and ribavirin therapy in patients with chronic hepatitis C", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Serum chemokine levels are associated with the outcome of pegylated interferon and ribavirin therapy in patients with chronic hepatitis C", "subitem_title_language": "en"}]}, "item_type_id": "6", "owner": "1", "path": ["462"], "permalink_uri": "http://hdl.handle.net/10091/16244", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2013-02-13"}, "publish_date": "2013-02-13", "publish_status": "0", "recid": "3826", "relation": {}, "relation_version_is_last": true, "title": ["Serum chemokine levels are associated with the outcome of pegylated interferon and ribavirin therapy in patients with chronic hepatitis C"], "weko_shared_id": -1}
Serum chemokine levels are associated with the outcome of pegylated interferon and ribavirin therapy in patients with chronic hepatitis C
http://hdl.handle.net/10091/16244
http://hdl.handle.net/10091/16244d57d3a22-664b-4684-b8cc-14358d09db1f
名前 / ファイル | ライセンス | アクション |
---|---|---|
Serum_Chemokine_Levels_Are_Associated_Outcome_ Pegylated_Interferon.pdf (210.2 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2013-02-13 | |||||
タイトル | ||||||
言語 | en | |||||
タイトル | Serum chemokine levels are associated with the outcome of pegylated interferon and ribavirin therapy in patients with chronic hepatitis C | |||||
言語 | ||||||
言語 | eng | |||||
DOI | ||||||
識別子タイプ | DOI | |||||
関連識別子 | https://doi.org/10.1111/j.1872-034X.2011.00802.x | |||||
関連名称 | 10.1111/j.1872-034X.2011.00802.x | |||||
キーワード | ||||||
主題 | chemokines, core, interferon sensitivity determining region, MIP-1 beta, pegylated interferon, ribavirin | |||||
資源タイプ | ||||||
資源 | http://purl.org/coar/resource_type/c_6501 | |||||
タイプ | journal article | |||||
著者 |
Yoneda, Suguru
× Yoneda, Suguru× Umemura, Takeji× Joshita, Satoru× Ichijo, Tetsuya× Matsumoto, Akihiro× Yoshizawa, Kaname× Katsuyama, Yoshihiko× Ota, Masao× Tanaka, Eiji |
|||||
信州大学研究者総覧へのリンク | ||||||
氏名 | Umemura, Takeji | |||||
URL | http://soar-rd.shinshu-u.ac.jp/profile/ja.ymSpgpkh.html | |||||
信州大学研究者総覧へのリンク | ||||||
氏名 | Joshita, Satoru | |||||
URL | http://soar-rd.shinshu-u.ac.jp/profile/ja.PeLNbVym.html | |||||
信州大学研究者総覧へのリンク | ||||||
氏名 | Ota, Masao | |||||
URL | http://soar-rd.shinshu-u.ac.jp/profile/ja.ZefVOFkh.html | |||||
信州大学研究者総覧へのリンク | ||||||
氏名 | Tanaka, Eiji | |||||
URL | http://soar-rd.shinshu-u.ac.jp/profile/ja.HFDCHekh.html | |||||
出版者 | ||||||
出版者 | WILEY-BLACKWELL | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | HEPATOLOGY RESEARCH. 41(6):587-593 (2011) | |||||
書誌情報 |
HEPATOLOGY RESEARCH 巻 41, 号 6, p. 587-593, 発行日 2011-06 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Aim: Serum chemokine levels and amino acid substitutions in the interferon-sensitivity determining region (ISDR) and core region have been associated with treatment outcome of pegylated interferon and ribavirin therapy in genotype 1 hepatitis C virus (HCV)-infected patients. The present study was conducted to clarify the association between serum chemokines and treatment outcome in patients with chronic HCV-1 infection in a Japanese cohort. Methods: A total of six serum chemokines were quantified before, during and after pegylated interferon and ribavirin treatment in 79 genotype 1 chronic HCV patients using a multiple bead array system. Viral ISDR and core region variants were determined by direct sequencing. Results: The baseline serum levels of eotaxin, IP-10 and RANTES were significantly higher in chronic HCV patients than in controls. High levels of eotaxin and macrophage inflammatory protein (MIP)-1 beta before therapy and more than two mutations in the ISDR were associated with a sustained virological response, and patients with more than two mutations in the ISDR also had significantly higher MIP-1 beta levels. Receiver-operator curve analysis showed a 77% sensitivity and 73% specificity for predicting an SVR using MIP-1 beta values. Conclusion: Serum MIP-1 beta levels may predict the response to HCV treatment with pegylated interferon and ribavirin and are associated with amino acid substitutions in the ISDR. | |||||
資源タイプ(コンテンツの種類) | ||||||
内容記述タイプ | Other | |||||
内容記述 | Article | |||||
ISSN | ||||||
収録物識別子タイプ | PISSN | |||||
収録物識別子 | 1386-6346 | |||||
書誌レコードID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AA11140867 | |||||
PubMed | ||||||
識別子タイプ | PMID | |||||
関連識別子 | https://pubmed.ncbi.nlm.nih.gov/21504519 | |||||
関連名称 | 21504519 | |||||
権利 | ||||||
権利情報 | The definitive version is available at www.blackwell-synergy.com | |||||
出版タイプ | ||||||
出版タイプ | AM | |||||
出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||
WoS | ||||||
表示名 | Web of Science | |||||
URL | http://gateway.isiknowledge.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=ShinshuUniv&SrcApp=ShinshuUniv&DestLinkType=FullRecord&DestApp=WOS&KeyUT=000290963400012 |